Immix Biopharma, Inc.
corporate_fare Company Profile
Immix Biopharma, Inc. (NASDAQ:IMMX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for IMMX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for IMMX spans 8-K, 10-Q, 424B5, FWP.
Recent high-impact activity:
- Immix Posts Q3 Loss, $340.9M Cash Into Mid-2028, Adds Two Commercial Leads
- Immix Biopharma Posts $35.6M Nine-Month Loss, Holds $336.3M Cash After $117.2M Raise
- Immix Biopharma Formalizes $125M Underwritten Offering with J.P. Morgan, Netting $117.1M
- Immix Biopharma Prices $125M Underwritten Offering at $11.00/Share
- Immix Biopharma Reports 89% Complete Response Rate in NEXICART-2, Potential to Reach 98%
Financial Snapshot
Short Interest & Short Volume
9.24 days to coverFINRA reported short interest of 11,254,167 shares in IMMX as of the October 30, 2026 settlement, a 5.1% increase from the prior period — about 9.2 days to cover at its recent average daily volume. On November 19, 2026, 67.5% of IMMX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IMMX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-29.
Underwritten Offering Priced · Dilution Impact
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →